Advertisement
Advertisement
VCYT
Veracyte, Inc.
25.39
USDSponsored
+1.23
+5.11%
Nov 09, 13:32 UTC -5
Open
Veracyte, Inc. (VCYT) Earnings
VCYT Earnings Reports
Positive Surprise Ratio
VCYT beat 32 of 44 last estimates.
73%
Next Report
Date of Next Report
Feb 22, 2027
Estimate for Q4 26 (Revenue/ EPS)
$157.33M
/$0.44
Implied change from Q3 26 (Revenue/ EPS)
+3.68%
/-13.73%
Implied change from Q4 25 (Revenue/ EPS)
+11.87%
/-13.73%
Veracyte, Inc. earnings per share and revenue
On Nov 04, 2026, VCYT reported earnings of 0.51 USD per share (EPS) for Q3 26, beating the estimate of 0.41 USD, resulting in a 21.78% surprise. Revenue reached 151.75 million, compared to an expected 150.39 million, with a 0.91% difference. The market reacted with a -54.30% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 0.44 USD, with revenue projected to reach 157.33 million USD, implying an decrease of -13.73% EPS, and increase of 3.68% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
GLOBUS MEDICAL INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.22
Actual
$1.23
Surprise
+0.75%
Teleflex Incorporated
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.92
Actual
$2.63
Surprise
+36.82%
Pulse Biosciences, Inc Common Stock (DE)
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.32
Surprise
+14.05%
TransMedics Group, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.29
Actual
$0.51
Surprise
+71.31%
Mettler-Toledo International
Report Date
Nov 05, 2026 For Q3 26
Estimate
$12.21
Actual
$12.57
Surprise
+2.90%
Tandem Diabetes Care, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.10
Surprise
+59.55%
Delcath Systems Inc
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.08
Actual
$0.17
Surprise
+300.00%
Orthofix Medical Inc. Common Stock (DE)
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.27
Actual
$0.18
Surprise
+166.59%
Treace Medical Concepts, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.19
Surprise
+26.67%
Envoy Medical, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.68
Actual
-$0.50
Surprise
+26.47%
FAQ
What were Veracyte, Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Veracyte, Inc. reported EPS of $0.51, beating estimates by 21.78%, and revenue of $151.75M, 0.91% above expectations.
How did the market react to Veracyte, Inc.'s Q3 2026 earnings?
The stock price moved down -54.3%, changed from $52.52 before the earnings release to $24.00 the day after.
When is Veracyte, Inc. expected to report next?
The next earning report is scheduled for Feb 22, 2027.
What are the forecasts for Veracyte, Inc.'s next earnings report?
Based on --
analysts, Veracyte, Inc. is expected to report EPS of $0.44 and revenue of $157.33M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.